Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials

• Published in: PloS one 2010-01, Vol.5 (1), p.e8781
• Main Authors: Keller, Marla J, Mesquita, Pedro M M, Torres, N Merna, Cho, Sylvia, Shust, Gail, Madan, Rebecca P, Cohen, Hillel W, Petrie, Julie, Ford, Tara, Soto-Torres, Lydia, Profy, Albert T, Herold, Betsy C
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Antiviral activity; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - pharmacokinetics; Antiviral Agents - pharmacology; Bioavailability; Biological activity; Biological Availability; Clinical trials; Clinical Trials as Topic; Coitus; Comparative analysis; Disease prevention; Fluorescence; Gels; Health aspects; Herpesvirus 2, Human - drug effects; HIV; HIV-1 - drug effects; Human immunodeficiency virus; Humans; Infection; Infections; Infectious Diseases/HIV Infection and AIDS; Infectious Diseases/Sexually Transmitted Diseases; Medical research; Microbicides; Migraine; Pharmacodynamics; Pharmacokinetics; Pharmacology; Plaque assay; Sampling methods; Semen; Sex; Sexual intercourse; Vagina; Virology/Antivirals, including Modes of Action and Resistance; Virology/Immunodeficiency Viruses; Women's Health/Sexually Transmitted Diseases; Womens health
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0008781

The pharmacokinetics and pharmacodynamics of vaginal microbicides are typically assessed among sexually abstinent women. However, the physical act of sex may modulate gel distribution, and preclinical studies demonstrate seminal plasma interferes with the antiviral activity of several microbicides. This study compared the biological activity and concentration of PRO 2000 in cervicovaginal lavage (CVL) collected in the absence or following coitus. CVL samples were collected from ten heterosexual couples at baseline, after sex, after a single dose of 0.5% PRO 2000 gel and sex, and after gel application without sex. The impact of CVL on HIV-1 infection of TZM-bl cells and HSV-2 infection of CaSki cells was monitored by luciferase and plaque assay, respectively. PRO 2000 concentrations were measured by fluorescence. CVL collected after PRO 2000 application significantly inhibited HIV-1 and HSV-2 (p = 0.01). However, the antiviral activity was reduced following sex and no significant protective effect was observed in postcoital CVL obtained in the presence compared to the absence of PRO 2000 for HIV (p = 0.45) or HSV-2 (p = 0.56). Less PRO 2000 was recovered in postcoital CVL, which, in conjunction with interference by seminal plasma, may have contributed to lower antiviral activity. Postcoital responses to PRO 2000 differ from precoital measures and the results obtained may provide insights into the clinical trial findings in which there was no significant protection against HIV-1 or HSV-2. Postcoital studies should be incorporated into clinical studies before embarking on large-scale efficacy trials.